Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotristat etiprate was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.
This article or press release has no online content. Please download the associated documents for more information.
You are now leaving the Ipsen Group section. If you would like to visit an affiliate section, please click Continue. The information provided on this section may not necessarily be applicable to the Ipsen Group.